No Prescription |
 |
 | ||
|
Zomig Generic Zolmitriptan |
|
| ||
No Prescription » Prescription Drugs 17 » Zomig Generic Zolmitriptan Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Zolmitriptan is used for: Treating acute migraine headaches with or without aura (flashing lights wavy lines dark spots) in adults. It is not intended to prevent migraines. Zolmitriptan is a headache medicine. It is believed to work by narrowing the blood vessels around the brain. Zolmitriptan also reduces substances in the body that can trigger headache pain nausea sensitivity to light and sound and other migraine symptoms. Buy Zomig Generic Zolmitriptan and other Prescription Drugs 17 products online at Medstore. 3745
About Zomig Generic Zolmitriptan: Product Type: Prescription Drugs 17 Zomig ( Generic Zolmitriptan ) Zomig (Generic Zolmitriptan) Generic Zolmitriptan 2.5mg 3 Tablets Generic Zolmitriptan Zomig
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
